Gastroesophageal reflux disease (GERD) has been reported to be significantly associated with chronic rhinosinusitis, but the strength of the association is still debated.
Aims
To evaluate the strength of the association between gastritis/GERD and non-allergic rhinitis (NAR)/allergic rhinitis (AR)/sinusitis.
Methods
We investigated 2887 subjects aged 20–84 years, who underwent a clinical visit in seven Italian centres (Ancona, Palermo, Pavia, Terni, Sassari, Torino, Verona) within the study on Gene Environment Interactions in Respiratory Diseases, a population-based multicase-control study between 2008 and 2014. Subjects were asked if they had doctor-diagnosed “gastritis or stomach ulcer (confirmed by gastroscopy)” or “gastroesophageal reflux disease, hiatal hernia or esophagitis”. The association between NAR/AR/sinusitis and either gastritis or GERD was evaluated through relative risk ratios (RRR) by multinomial logistic regression.
Results
The prevalence of gastritis/GERD increased from subjects without nasal disturbances (22.8% = 323/1414) to subjects with AR (25.8% = 152/590) and further to subjects with NAR (36.7% = 69/188) or sinusitis (39.9% = 276/691). When adjusting for centre, sex, age, education level, BMI, smoking habits and alcohol intake, the combination of gastritis and GERD was associated with a four-fold increase in the risk of NAR (RRR = 3.80, 95% CI 2.56–5.62) and sinusitis (RRR = 3.70, 2.62–5.23) with respect to controls, and with a much smaller increase in the risk of AR (RRR = 1.79, 1.37–2.35)..
Conclusion
The study confirmed the association between gastritis/GERD and nasal disturbances, which is stronger for NAR and sinusitis than for AR.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
GERD
Gastroesophageal reflux disease
NAR
Non-allergic rhinitis
AR
Allergic rhinitis
GEIRD
Gene-Environment Interactions in Respiratory Diseases
ECRHS
European Community Respiratory Health Survey
Background
Rhinitis is a global common problem and is defined as the presence of at least one of the following: congestion, rhinorrhea, sneezing, nasal itching, and nasal obstruction. The two major classifications are allergic (AR) and non-allergic rhinitis (NAR) [1]. NAR occurs when obstruction and rhinorrhea are related to non-allergic, non-infectious triggers such as a change in the weather, exposure to caustic odors or cigarette smoke, barometric pressure differences, etc. [2]. The prevalence of AR in adults in Europe ranged from 17 to 28.5% [3], while NAR affects up to 30% of individuals in the Western population [4].
Gastro-esophageal reflux disease (GERD) is also a worldwide prevalent condition, which is on the rise in Europe and North America [5]. Hence also esophageal and extraesophageal diseases associated with GERD are expected to increase. Some of the well-established extraesophageal manifestations are reflux-induced cough, laryngitis, asthma and dental erosion. Other manifestations, such as sinusitis, pharyngitis, idiopathic pulmonary fibrosis, and recurrent otitis media, are proposed but not established as it is unclear whether GERD is a significant causal or exacerbating factor [6].
Anzeige
Since both chronic rhinosinusitis and GERD are highly prevalent, it is difficult to establish a direct relation between them, as they can easily coexist independently [7]. Moreover, while the association between GERD and nasal disorders gained support in children [8, 9], in adults the evidence is still sparse. Several studies focused on the possible correlation of GERD and sinusitis [10‐12], which have been reported to occur together more frequently than expected [13]. At first, several reviews did not find out a clear evidence-based relationship between Chronic rhinosinusitis and GERD [13‐15]. However, in the last years the association between GERD and sinusitis gained support. Two European studies found that the SNOT (Sino-Nasal Outcome Test) score significantly increased among patients with GERD, suggesting a direct role of GERD in the development of chronic rhinosinusitis [10, 16]. A large cohort study based on Taiwan Health Care Utilization database by Lin et al. [17] found that the risk of developing chronic rhinosinusitis was more than doubled in cases with newly diagnosed GERD with respect to controls matched for sex, age and comorbidities. In a population-based Brazilian survey the diagnosis of gastritis/ulcer/gastroesophageal reflux was associated with higher prevalence of rhinosinusitis symptoms in multivariable analysis [18]. An Italian study on a small series undergoing both nasal cytology and esophageal manometry and 24-h pH-impedance monitoring showed that NAR with neutrophils strongly correlated with higher acid exposure time and refluxes number [19]. On the basis of this accumulating evidence, the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis [20] assigned grade B evidence to support the association between chronic rhinosinusitis and GERD, although causation could not be clearly demonstrated.
The association between GERD and AR is more questioned. The recent International Consensus Statement on Allergic Rhinitis does not even mention GERD at all as a potential risk factor [21]. The situation is complex, as several studies which found an association between GERD and nasal disorders did not distinguish between NAR and AR [22].
Since nasal disorders are highly prevalent diseases that can have a deep impact on individual life and healthcare system, it is important to identify causative and triggering factors, and their comorbidities. The present study aimed to investigate the relation between gastritis/GERD and allergic and non-allergic rhinitis in a large population-based case–control study.
Methods
Study design
The study was performed in the frame of the GEIRD (Gene-Environment Interactions in Respiratory Diseases) study, a multicase-control study on respiratory health, involving seven Italian centers, three located in Northern Italy (Verona, Pavia, Turin), two in Central Italy (Ancona, Terni) and two in the major islands (Sassari in Sardinia and Palermo in Sicily) [23]. The study comprised a screening phase and a clinical phase. In the screening phase a screening questionnaire was mailed to random samples from the general population aged 20–84 years, while in the clinical phase subjects reporting symptoms suggestive of chronic bronchitis, asthma or rhinitis, as well as a sample of subjects without respiratory symptoms, were invited to a local Respiratory/Allergy Unit, in order to undergo interviews and clinical tests. In particular, participating subjects were administered a modified version of the ECRHS (European Community Respiratory Health Survey) clinical questionnaire, including detailed questions on socio-demographic characteristics, smoking habits and other lifestyle factors, respiratory symptoms and other disturbances, drug consumption [23; available at www.geird.org]. In each center, the GEIRD study was approved by the local ethics committee and written consent was obtained from each participant.
Anzeige
Fifty-nine percent (17,972/30,349) of selected subjects answered the screening questionnaire, while 2,945 subjects out of 7,739 participated in the clinical visit between 2008 and 2014, yielding a participation rate of 40.1%.
Nasal disorders
Subjects were classified as having "rhinitis" if they answered affirmatively to at least one of the following questions: "Do you have any nasal allergies including hay fever?", "During your lifetime have you ever had any nasal allergies including hay fever?", "Have you ever had a problem with sneezing, or a runny or a blocked nose when you did not have a cold or the flu?". Rhinitis was further classified as allergic rhinitis (AR) and non-allergic rhinitis (NAR), according to the presence or absence of atopy. Subjects were also asked whether they ever suffered from nasal polyps.
Treatments for nasal disorders were assessed by the following questions "Have you used any of the following nasal medicines (e.g. nasal sprays, inhaled powders or drops) for the treatment of your nasal disorders?" and "Have you used any of the following pills, capsules, or tablets for the treatment of your nasal disorder?".
Other respiratory disorders
Asthma was deemed present when the subject reported physician-diagnosed asthma. The disease was further classified in: current asthma if the subject took any medicine for asthma or had had an attack of asthma or reported any asthma-like symptom (wheezing, chest tightness or shortness of breath) in the previous 12 months; past asthma otherwise.
Chronic cough and phlegm was defined by a positive answer to the question: “Have you had coughing and phlegm on most days for a minimum of 3 months a year and for at least 2 successive years?”. Doctor-diagnosed chronic bronchitis was defined by an adfirmative answer to the question: “Have you ever been told by a doctor that you have or had chronic bronchitis, chronic obstructive pulmonary disease (COPD) or emphysema?”.
Atopy
Atopy was established by a positive skin prick test in which the following panel of allergens were used: Cupressus arizonica, Dermatophagoides pteronyssinus, Artemisia vulgaris, Dermatophagoides farinae, Ambrosia artemisifolia, Alternaria tenuis, Parietaria judaica, dog dandruff, Corylus avellana, cat, Olea europea, Betula verrucosa, Cladosporium herbarum, and Phleum pratense. The result was considered positive if, after twenty minutes, the average wheal diameter was 3 mm greater than the negative control.
Gastritis/gastroesophageal reflux
Subjects were classified as having gastritis if they answered positively to the question "Has a doctor told you having or have had gastritis or stomach ulcer (confirmed by a gastroscopy)?" Similarly, subjects were considered having gastroesophageal reflux disease (GERD) if they answered affirmatively to the question "Has a doctor told you having or have had gastroesophageal reflux disease, hiatal hernia or esophagitis?”.
Lifestyle factors
Subjects were classified as normal weight (BMI < 25 kg/m2), overweight (25 ≤ BMI < 30 kg/m2), or obese (BMI ≥ 30 kg/m2). They were considered active when reporting to exercise for at least 1 h getting out of breath or sweating with a frequency of at least 2–3 times a week.
Anzeige
With regard to smoking habits, subjects were classified as (1) current smokers, if they reported to have smoked at least one cigarette per day or one cigar a week for as long as one year, and also in the last month; (2) ex-smokers if they had smoked the same minimum amount previously reported, but had stopped smoking for at least one month before the interview; (3) never smokers otherwise. As regards alcohol consumptions, subjects were classified as drinkers and nondrinkers.
Statistical analyses
Significance of the association between AR/NAR/sinusitis and potential risk factors was evaluated by Fisher's exact test or Chi-squared test. The same statistical tests were used to evaluate the association between gastritis/gastroesophageal reflux and other risk factors.
Multivariable analysis was accomplished by a multinomial logistic regression model [24], where the response variable was nasal symptoms: 0 = no symptom (base outcome), 1 = allergic rhinitis, 2 = non-allergic rhinitis, 3 = sinusitis. Gastroesophageal reflux (none/gastritis/reflux/both gastritis and reflux) was the explanatory variable, while sex, age (per 10 year increase), age at completing full-time education (< 18, 18–21, ≥ 22 years), BMI (< 25, 25–29.9, ≥ 30 kg/m2), smoking habits (never smoker, past smoker, current smoker), alcohol intake (nondrinker, drinker), were the potential confounders. Results were synthesized through the relative risk ratios (RRR), adjusting standard errors for intra center correlation. Analyses were performed with STATA statistical software, release 14 (StataCorp, College Station, TX, USA) and statistical significance was set at p < 0.05.
Results
Description of controls and cases of AR/NAR/sinusitis, as a function of main risk factors
2887 subjects participated in the clinical visit and they had a mean age (SD) of 50.1 (13.2) years. Cases of AR and sinusitis were younger (mean age ± SD = 46.0 ± 11.8 and 48.7 ± 11.9 years, respectively) than controls and cases of NAR (52 ± 13.7 and 54.6 ± 14 years, respectively) (p < 0.001). Controls and cases of NAR had a lower level of education and physical activity, a higher prevalence of obesity than cases of AR and sinusitis. Atopy, which was used to define NAR and AR, had a prevalence of 27% in controls and 58% in cases of sinusitis. Nasal polyps were rare in controls and cases of NAR, and more common in cases of AR and sinusitis. Use of antihistamines and steroids was frequent among cases of AR, and rare among cases of NAR, while the use of vasoconstrictors was similar in the two groups. Sex, smoking habits and alcohol intake did not significantly differ between cases and controls (Table 1).
Table 1
Number and percent of controls, cases of non-allergic rhinitis (NAR), allergic rhinitis (AR) and sinusitis as a function of main socio-demographic, lifestyle, and clinical characteristics
Controls (n = 1416)
n(%)
AR (n = 592)
n(%)
NAR (n = 188)
n(%)
Sinusitis (n = 691)
n(%)
p value
Sex
0.068
Male
729 (51.5)
317 (53.5)
87 (46.3)
326 (47.2)
Female
687 (48.5)
275 (46.5)
101 (53.7)
365 (52.8)
Age (years)
< 0.001
20–34
144 (10.2)
95 (16.1)
12 (6.4)
70 (10.1)
35–44
339 (23.9)
194 (32.8)
34 (18.1)
218 (31.6)
45–54
388 (27.4)
191 (32.3)
61 (32.5)
218 (31.6)
55–64
254 (17.9)
72 (12.2)
36 (19.2)
119 (17.2)
≥ 65
291 (20.6)
40 (6.8)
45 (23.9)
66 (9.6)
Time at stopping education (years)
< 0.001
< 18
465 (33.1)
141 (24)
64 (34.8)
190 (27.7)
18–21
498 (35.5)
222 (37.8)
68 (37)
267 (38.9)
≥ 22
440 (31.4)
225 (38.3)
52 (28.3)
228 (33.3)
BMI (kg/m2)
0.030
< 25
681 (49.9)
328 (56.6)
94 (50.5)
355 (53.4)
25–29
475 (34.8)
187 (32.2)
62 (33.3)
236 (35.5)
≥ 30
208 (15.3)
65 (11.2)
30 (16.1)
74 (11.1)
Physical activity (times/week)
0.038
< 2–3 times
983 (69.9)
379 (64.6)
138 (74.2)
467 (67.9)
≥ 2–3 times
423 (30.1)
208 (35.4)
48 (25.8)
221 (32.1)
Smoking habits
0.577
No smoker
684 (49.4)
305 (52.6)
81 (43.8)
333 (49.3)
Ex smoker
411 (29.7)
158 (27.2)
60 (32.4)
200 (29.6)
Current smoker
290 (20.9)
117 (20.2)
44 (23.8)
142 (21.0)
Alcohol intake (No/Yes)
0.158
No drinker
875 (62.3)
349 (59.4)
121 (64.7)
399 (58.1)
Drinker
529 (37.7)
239 (40.6)
66 (35.3)
288 (41.9)
Atopy
< 0.001*
No
931 (72.7)
–
188 (100.0)
268 (41.9)
Yes
349 (27.3)
592 (100.0)
–
372 (58.1)
Nasal polyps (ever)
< 0.001
No
1396 (98.8)
564 (95.4)
185 (98.4)
632 (91.7)
Yes
17 (1.2)
27 (4.6)
3 (1.6)
57 (8.3)
Asthma
< 0.001
No
1807 (85.25)
225 (40.47)
109 (72.67)
328 (52.82)
Yes
107 (8.39)
238 (42.81)
29 (19.33)
213 (34.30)
Past
81 (6.35)
93 (16.73)
12 (8.00)
80 (12.88)
Chronic chough and phlegm
< 0.001
No
1.338 (95.1)
524 (88.81)
154 (83.24)
588 (85.59)
Yes
69 (4.9)
66 (11.19)
31 (16.76)
99 (14.41)
Doctor-diagnosed chronic bronchitis
0.562
No
1236 (97.78)
521 (97.38)
156 (96.89)
587 (96.71)
Yes
28 (2.22)
14 (2.62)
5 (3.11)
20 (3.29)
Steroids (ever)
< 0.001
No
1302 (98.6)
422 (80.8)
160 (92.5)
491 (79.1)
Yes
18 (1.4)
100 (19.2)
13 (7.5)
130 (20.9)
Vasoconstrictors (ever)
< 0.001
No
1274 (96.4)
394 (75.3)
142 (81.6)
486 (77.8)
Yes
48 (3.6)
129 (24.7)
32 (18.4)
139 (22.2)
Antihistamines (ever)
< 0.001
No
1320 (99.7)
362 (69)
162 (93.1)
495 (78.8)
Yes
4 (0.3)
163 (31.1)
12 (6.9)
133 (21.2)
Significance of differences was computed by Fisher’s exact test or Chi-square test
*Computed only on controls and people with sinusitis
Anzeige
Description of controls and cases of gastroesophageal disorders, as a function of main risk factors
People with gastritis and/or gastroesophageal reflux were older and had attained a lower education level than people without these disorders (Table 2). Women more frequently reported gastritis and gastroesophageal reflux than men. Gastritis and gastroesophageal reflux were more common, respectively, in current smokers and overweight people.
Table 2
Number (percentage) of controls, cases of gastritis and gastroesophageal reflux, isolated or combined, as a function of main socio-demographic, lifestyle and clinical characteristics
No gastritis/reflux (n = 2128)
Gastritis only (n = 264)
Reflux only (n = 310)
Both Gastritis and Reflux (n = 278)
p value
Sex
0.034
Male
1101 (51.7)
131 (49.6)
159 (51.3)
118 (42.5)
Female
1027 (48.3)
133 (50.4)
151 (48.7)
160 (57.6)
Age (years)
< 0.001
20–34
282 (13.3)
11 (4.2)
19 (6.1)
15 (5.4)
35–44
601 (28.2)
61 (23.1)
78 (25.2)
70 (25.2)
45–54
648 (30.5)
68 (25.8)
87 (28.1)
81 (29.1)
55–64
323 (15.2)
46 (17.4)
61 (19.7)
63 (22.7)
> 65
274 (12.9)
78 (29.6)
65 (21.0)
49 (17.6)
Time at stopping education (years)
< 0.001
< 18
578 (27.4)
111 (42.4)
93 (30.4)
103 (37.5)
18–21
806 (38.2)
73 (27.9)
111 (36.3)
99 (36.0)
≥ 22
727 (34.4)
78 (29.8)
102 (33.3)
73 (26.5)
BMI
0.021
< 25
1104 (53.8)
137 (53.5)
130 (43.6)
126 (46.8)
25–29
679 (33.1)
83 (32.4)
125 (42.0)
102 (37.9)
≥ 30
271 (13.2)
36 (14.1)
43 (14.4)
41 (15.2)
Physical activity (hours/week)
0.112
< 2/3
1428 (67.7)
194 (74.0)
217 (70.5)
198 (71.5)
≥ 2/3
683 (32.4)
68 (26.0)
91 (29.5)
79 (28.5)
Smoking habits
0.006
No smoker
1059 (50.9)
103 (40.4)
154 (50.2)
128 (47.4)
Ex smoker
588 (28.2)
92 (36.1)
105 (34.2)
79 (29.3)
Current smoker
435 (20.9)
60 (23.5)
48 (15.6)
63 (23.3)
Alcohol intake (no/yes)
0.793
No drinker
1284 (60.9)
165 (63.2)
182 (59.1)
168 (60.4)
Drinker
826 (39.1)
96 (36.8)
126 (40.9)
110 (39.6)
Atopy
0.485
No
1009 (51.1)
123 (53.0)
131 (49.6)
143 (55.6)
Yes
964 (48.9)
109 (47.0)
133 (50.4)
114 (44.4)
Nasal polyps
0.238
No
2049 (96.6)
253 (96.2)
291 (94.5)
271 (97.5)
Yes
73 (3.4)
10 (3.8)
17 (5.5)
7 (2.5)
Significance of differences was evaluated by Fisher’s exact test or Chi-square test
Atopy and nasal polyps, the level of physical activity and alcohol intake did not significantly change as a function of gastritis/gastroesophageal reflux.
Description of controls and cases of AR/NAR/Sinusitis, as a function of gastroesophageal disorders
Gastritis/gastroesophageal reflux were strongly associated with nasal disorders. The prevalence of gastritis/reflux was 5.9% in controls, it slightly increased to 7.5% in cases of allergic rhinitis and further to 18.1% and 15.8% in cases of NAR and sinusitis, respectively (Table 3).
Table 3
Prevalence of gastroesophageal disorders (gastritis/GERD) in controls, rhinitis, allergic rhinitis and sinusitis subjects
Controls (n = 1414) n(%)
AR (n = 590)
n(%)
NAR (n = 188)
n(%)
Sinusitis (n = 691)
n(%)
p value
Gastritis/reflux
< 0.001
No gastritis/GERD
1091 (77.2)
438 (74.2)
119 (63.3)
415 (60.1)
Gastritis/GERD
323 (22.8)
152 (25.8)
69 (36.7)
276 (39.9)
Gastritis only
108 (7.6)
43 (7.3)
21 (11.2)
81 (11.7)
GERD Only
132 (9.3)
65 (11)
14 (7.5)
86 (12.5)
GERD and Gastritis
83 (5.9)
44 (7.5)
34 (18.1)
109 (15.8)
p values were computed by Pearson's Chi-square test
Multivariable analyses
The combination of gastritis and GERD was associated with a four-fold increase in the risk of NAR (RRR = 3.80, 95% CI 2.56–5.62) and sinusitis (RRR = 3.70, 2.62–5.23) with respect to people without these disorders, and with a much smaller increase in the risk of AR (RRR = 1.79, 1.37–2.35). The risk of nasal disorders was significanlty increased, although to a smaller extent, in subjects reporting gastritis alone, while GERD was significantly associated with sinusitis but not with either NAR or AR (Fig. 1).
Fig. 1
Association between nasal disorders and gastritis/gastroesophageal reflux. Relative Risk Ratios (RRR) were estimated by a multinomial regression model, adjusting for sex, age, education level, BMI, smoking habits, alcohol intake. Columns are RRRs, bars are 95% confidence inervals
×
Anzeige
A regards the other factors, the risk of NAR was higher in women than men (RRR = 1.28, 1.19–1.37). Moreover, the risk of AR and sinusitis decreased with advancing age (RRR per 10-year increase = 0.70, 0.63–0.79 and 0.79, 0.66–0.95, respectively). The risk of NAR was higher in current smokers than never smokers (RRR = 1.48, 1.16–1.89), and in people with medium than low education (RRR = 1.12, 1.00–1.26). With respect to normoweight, obesity was associated with a lower risk of AR (RRR = 0.75, 0.58–0.97) and sinusitis (RRR = 0.79, 0.65–0.95). The risk of sinusitis was slightly higher in past smokers than never smokers (RRR = 1.18, 1.01–1.38) and in alcohol drinkers than non-drinkers (RRR = 1.23, 1.02–1.47).
Discussion
The main findings of the present study are:
1.
Gastritis and GERD were strongly associated with non-allergic nasal diseases (NAR and sinusitis) and, to a much smaller extent, to allergic rhinitis, both in univariable and multivariable analysis.
2.
The association was rather strong for the combination of gastritis and GERD, and rather weak for gastritis alone, and nearly absent for GERD alone. Subjects self-reporting both gastrointestinal diseases had probably a more severe condition than the other subjects.
3.
Nasal polyps, while nearly absent in controls and cases of NAR, were found in 5% of cases of AR and 8% of cases of sinusitis. Their prevalence was not significantly affected by gastritis/GERD.
4.
The risk of AR and sinusitis decreased with advancing age and in obese people. As regards lifestyle factors, NAR was associated with current smoking, and sinusitis with alcohol consumption.
The present multicase-control study showed that upper gastrointestinal disorders were strongly associated with non-allergic nasal disorders: the prevalence of gastritis and/or GERD was 22.8% in controls, only slightly increased in cases of AR (25.8%), and peaked up in cases of non-allergic nasal disorders, such as NAR (36.7%) and sinusitis (39.9%). These findings were confirmed in multivariable analysis, where the combination of gastritis and GERD was associated with a nearly four-fold increase in the risk of NAR and sinusitis, while the risk of AR was less than doubled.
These findings are in agreement with the current literature. As already mentioned, the association between chronic rhinosinusitis and GERD has been acknowledged by the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis [20], although with moderate evidence. On the other hand, the association between AR and GERD is not even mentioned by the recent International Consensus Statement on Allergic Rhinitis [21]. A recent study supported GERD involvement in the development of NAR, since patients with NAR displayed a high level of pepsin in saliva samples, especially in the postprandial period, compared to healthy controls [4].
Nasal polyps were not significantly related to gastritis/GERD in the present study. According to Lin et al. [17] the association between GERD and chronic rhinosinusitis was stronger in subjects without than with nasal polyps.
An interesting approach to the relation between GERD and nasal disorders consists in verifying whether treatment of GERD could improve nasal symptoms especially in chronic rhinosinusitis refractory to clinical or surgical treatment. However, a recent review assessed the effect of treatment with proton pump inhibitors (PPIs) on chronic rhinosinusitis symptoms in four longitudinal studies, and found conflicting results [25].
Pathophysiological mechanisms
Several mechanisms have been proposed to explain the relation between acid reflux and chronic rhinosinusitis. Subjects with chronic rhinosinusitis have been shown to have more proximal gastroesophageal reflux than healthy controls [26].
First of all, gastric acid exposure may exacerbate inflammation within the mucosa of the upper airways and sinuses and impair mucociliary motility, causing obstruction of sinus ostia and favouring recurrent infections [27‐29].
A second mechanism could be vagally-mediated neuroinflammatory changes [11]. Autonomic dysfunction can lead to reflex sinonasal swelling and inflammation, leading to blockage of the ostia. Wong et al. [30] gave experimental support to this hypothesis, showing that infusion of saline with hydrochloric acid in the lower esophagus increased nasal mucus production and nasal symptom score.
Also a role of Helicobacter pylori (H. pylori) has been proposed, as the microorganism has been detected not only in the stomach but also in oral and nasal mucosa [31]. In particular, H. pylori has been found in nasal polyps but not in control tissue [32], and in patients who have both GERD and chronic rhinosinusitis [33]. Moreover, H. Pylori causes not only gastritis but also systemic inflammation, which can involve also the nasal mucosa.
Strengths and limitations
The present study has several strengths. It involved seven centres scattered from Northern to Southern Italy, 1,471 cases of nasal disorders and 1,416 controls, and information was collected by standardized methods (questionnaire and skin prick test).
However, some limitations should be acknowledged. First of all, the cross-sectional design did not allow to properly infer the cause-effect relationship between GERD/gastritis and NAR. Indeed, to prove such a cause effect relation, longitudinal studies with an adequate number of patients are needed. Second, while information on nasal disorders was based on questionnaire and objective measurement (skin prick test), information on gastritis and GERD was exclusively derived by questionnaire. Gastritis alone apparently had larger effects on AR and NAR than GERD alone. It should be reminded that the question on gastritis was probably more reliable as it involved not only medical diagnosis but also objective assessment (gastroscopy), while the question on GERD put together different diseases (GERD, hiatal hernia, or esophagitis) and did not refer to instrumentally confirmed diagnosis. Moreover, subjects who reported both gastritis and GERD probably had a more clear-cut gastrointestinal disease than those reporting only one disease. In turn, improvement in exposure definition allowed to better assess association with nasal disorders.
Conclusions
According to the present study, gastritis and GERD were strongly associated with nasal disorders, in particular non-allergic ones (NAR and sinusitis). On the other hand AR, which was defined by symptoms and positive skin prick test, has an IgE-mediated pathogenesis and is only mildly affected by irritant substances, such as acid reflux.
Nevertheless, to prove a causal effect relationship, prospective studies with a significant number of patients are needed. In particular randomized controlled trials should verify whether reflux treatment also improve concomitant nasal disorders.
Acknowledgements
Not Applicable
Ethics approval and consent to participate
Ethics approval was obtained in each centre involved in the GEIRD study from the appropriate ethics committee (Comitato Etico dell’Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona; Comitato Etico dell’Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello di Palermo; Comitato di Bioetica della Fondazione IRCCS Policlinico San Matteo di Pavia; Comitato Etico delle Aziende Sanitarie dell’Umbria di Perugia; Comitato di Bioetica dell’Azienda Sanitaria Locale di Sassari; Comitato Etico dell’Azienda Sanitaria Locale TO/2 di Torino; Comitato Etico per la Sperimentazione dell’Azienda Ospedaliera Istituti Ospitalieri di Verona). Information on the purpose of the survey and participants’ rights according to then current Italian law (Decreto Legislativo 30 giugno 2003, n. 196) were enclosed to the questionnaire administered by mail. Individuals were free to answer or not answer the questionnaire, as denoted by the non-negligible nonresponse rate. Hence, consent to participate was implied by the answer to the questionnaire, and this form of consent was approved by the local Ethics Committee.
Consent for publication
Not applicable.
Competing interests
G. Verlato is Section Editor of BMC Pulmonary Medicine, for the Section Epidemiology and Public Health. G. Verlato received financial support from BioMed Central to participate in the 2014 and 2015 Congresses of the European Respiratory Society. All remaining authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.
Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.
Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.
Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
